iBio Secures $26 Million in Financing to Advance Preclinical Programs and Extend Cash Runway

iBio, a biotech company, has reported Q2 FY26 financial results and provided a corporate update. The company secured $26 million in PIPE financing, progressed its pipeline with new preclinical data and scientific presentations, and closed a $26 million private placement financing led by Frazier Life Sciences. The net proceeds will fund key preclinical cardiometabolic programs, including IBIO-610 and IBIO-600, and extend the company's cash runway into Q3 2028.